BioLargo (BLGO) Q4 2024 earnings summary

Executive summary

• Achieved record revenues for the tenth consecutive year, with a 45% year-over-year increase to nearly $18 million, continuing a multi-year growth trend.

• Core strategy of capital-efficient innovation and partnership is yielding results across multiple subsidiaries, with significant progress in Pooph, Clyra Medical, battery technology, and PFAS solutions.

• Generated over $5 million in cash from odor control products, reducing reliance on equity financing.

• Expanded workforce to 44 employees plus high-level consultants, building critical mass and expertise to accelerate development and market adoption.

Financial highlights

• 2024 revenues reached $17,779,000, up 45% year-over-year.

• Net loss for 2024 was $4,347,000, a 6% decrease from 2023; $3,490,000 of this from Clyra Medical.

• Operating income from Odor-No-More reached $5.9 million, with a 36% revenue increase.

• BLEST engineering division grew third-party revenue by 183%, reducing its operating loss to $1.45 million.

• Working capital stood at $4,489,000, with $3,548,000 in cash and cash equivalents; stockholders’ equity at year-end was $6,056,000.

Outlook and guidance

• Anticipates continued growth and improved financial performance, with expectations to replicate or exceed 2024 results.

• Clyra Medical is progressing toward national rollout of surgical irrigation products after successful manufacturing inspection, with significant revenue potential upon launch.

• Battery technology (Spartan Cell) is targeting third-party validation in May, a key milestone for commercialization and potential factory franchise model.

• PFAS solutions are gaining traction through teaming agreements and pilot projects, with regulatory momentum supporting adoption.

• Continued focus on commercializing new technologies and expanding product reach through licensing and partnerships.